Related Experiment Video

Updated: Aug 6, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
08:45

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

Recent advances in antifungal pharmacotherapy for invasive fungal infections

Jason C Gallagher1, Conan MacDougall, Elizabeth S Dodds Ashley

  • 1Hahnemann University Hospital, Broad and Vine Sts, Mail Stop 451, Philadelphia, PA 19102, USA. jason.gallagher@tenethealth.com.

Expert Review of Anti-Infective Therapy
|October 16, 2004
PubMed

Insights

New antifungal medications, including echinocandins and voriconazole, offer improved treatment options for invasive fungal infections. These advancements are crucial for managing serious infections in immunocompromised patients.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Invasive fungal infections (IFIs) pose significant health risks, with Candida and Aspergillus species being common culprits, especially in immunocompromised individuals.
  • Limited efficacy and toxicity of older antifungal agents historically restricted treatment options for IFIs.
  • The growing population of immunocompromised patients is expected to increase the incidence of IFIs.

Purpose of the Study:

  • To review recent advancements in antifungal pharmacotherapy.
  • To discuss the role of new antifungal agents in treating IFIs.
  • To explore the implications of new antifungals on combination therapy strategies.

Main Methods:

  • Literature review of recent developments in antifungal pharmacotherapy.
  • Analysis of clinical evidence for new antifungal agents like echinocandins and voriconazole.
  • Discussion of treatment guidelines and emerging therapeutic approaches for IFIs.

Main Results:

  • Introduction of lipid formulations of amphotericin B to reduce toxicity.
  • Development of echinocandins (e.g., caspofungin) and a new triazole (voriconazole) offering new treatment avenues.
  • Accumulating evidence supports the efficacy of these newer agents in managing IFIs.

Conclusions:

  • Recent advances in antifungal pharmacotherapy have significantly expanded treatment options for IFIs.
  • Newer agents like echinocandins and voriconazole are vital in managing serious fungal infections, particularly in complex and critically ill patients.
  • These developments are reshaping the landscape of antifungal combination therapy.

More Related Videos

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract07:42

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract

Published on: July 1, 2020

Quantifying the Antifungal Activity of Peptides Against Candida albicans06:45

Quantifying the Antifungal Activity of Peptides Against Candida albicans

Published on: January 13, 2023

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...